Solid Tumors Clinical Trials in Denver, Colorado

4 studies are recruiting for solid tumors in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Investigative Site US071, Denver, Colorado
    Locations
    229 in total
    Run by
    Incyte Corporation

    See if you can join NCT07522073 on ClinicalTrials.gov

  2. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institue At Healthone, Denver, Colorado
    Locations
    34 in total
    Run by
    Incyte Corporation

    See if you can join NCT06179160 on ClinicalTrials.gov

  3. JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

    This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Denver, Colorado
    Locations
    15 in total
    Run by
    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06386146 on ClinicalTrials.gov

  4. QTX3034 in Patients With KRAS G12D Mutation

    Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute (SCRI), Denver, Colorado
    Locations
    14 in total
    Run by
    Quanta Therapeutics

    See if you can join NCT06227377 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.